Skip to main content
US EQUITIES AFTER-HOURS CRYPTO 24/7
HALAL TRADING ROOM Sharia-screened signals
TERMINAL
XV

XVIPFStock

Healthcare · SE

$19.00 last close 2026-11-17
Open in terminalCompare
Price alert

Verdicts genuinely change. Free email alert the moment XVIPF's does — no target price to set, unlike a price alert.

Stable Ratio screen, 7 of 7 decided standards passing. No standard's deciding ratio sits within 3 points of its line. What would change it

Sharia status
COMPLIANT
Per our in-house ratio engine
7 of 7 pass our own screen — all 7 agree here
Purification 0.96% *HTR non-permissible income 0.97%
🕌Open research, not a fatwa — verify with your own scholar.

Trade setup

Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.

SEPARATE FROM SHARIAH
No active setup right now. The technical picture doesn't show a clear edge — check back when the trend or momentum shifts.

XVIPF is currently considered halal (Sharia-compliant), per our in-house ratio engine. See the full ratio breakdown and business-activity screen below for the reasoning.

This sits among 434 compliant Healthcare stocks we track. See compliant Healthcare stocks →

Market & analysts
Institutional own.
60.8%
of shares
0.96% *
Purification ratio (secondary provider, uncertain)
0.97%
Non-permissible income — HTR, from filings (2025-12-31)
60.8%
Institutional ownership

How the status reached this point

Compliant · status tracked since Nov 17, 2026

No change to XVIPF’s published status has been recorded since our daily status check began on Nov 17, 2026. What it read before then is not on record here.

Read once a day from our own screen, last on Nov 17, 2026. The per-methodology record is under “What changed, and when” in the in-house research.

Free email, sent when our compliance re-scan finds a change.

🕌 In-house Compliance Research

Computed from published company financials, balance sheet as of 2025-12-31. These ratios come from the issuer's own published statements rather than structured SEC data.

AAOIFI divides by the market cap: $974.9M as of 2026-09-08.

Business activity: cleared (no excluded categories detected)

AAOIFI Pass 3 of 3 ratios pass
RatioValueThresholdResult
Interest-bearing debt 1.39% 30.00% Pass(28.6pp buffer)
Interest-bearing investments 3.25% 30.00% Pass(26.7pp buffer)
Non-permissible income 0.97% 5.00% Pass(4.0pp buffer)
Usmani Pass 4 of 4 ratios pass
RatioValueThresholdResult
Interest-bearing debt 10.51% 33.00% Pass(22.5pp buffer)
Interest-bearing investments 12.30% 33.00% Pass(20.7pp buffer)
Non-liquid assets 83.43% at least 20.00% Pass(63.4pp above the floor)
Non-permissible income 0.97% 5.00% Pass(4.0pp buffer)
MSCI Pass 4 of 4 ratios pass
RatioValueThresholdResult
Interest-bearing debt 5.25% 33.33% Pass(28.1pp buffer)
Cash + interest-bearing securities 12.30% 33.33% Pass(21.0pp buffer)
Accounts receivable 16.57% 33.33% Pass(16.8pp buffer)
Non-permissible income 0.97% 5.00% Pass(4.0pp buffer)
FTSE Pass 4 of 4 ratios pass
RatioValueThresholdResult
Interest-bearing debt 5.25% 33.33% Pass(28.1pp buffer)
Cash + interest-bearing securities 12.30% 33.33% Pass(21.0pp buffer)
Accounts receivable 16.57% 50.00% Pass(33.4pp buffer)
Non-permissible income 0.97% 5.00% Pass(4.0pp buffer)
Dow Jones Islamic Market Pass 4 of 4 ratios pass

Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 0.97% 33.00% Pass(32.0pp buffer)
Cash + interest-bearing securities 2.27% 33.00% Pass(30.7pp buffer)
Accounts receivable 0.79% 33.00% Pass(32.2pp buffer)
Non-permissible income 0.97% 5.00% Pass(4.0pp buffer)
S&P Shariah Pass 4 of 4 ratios pass

Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 0.88% 33.00% Pass(32.1pp buffer)
Cash + interest-bearing securities 2.05% 49.00% Pass(46.9pp buffer)
Accounts receivable 0.71% 49.00% Pass(48.3pp buffer)
Non-permissible income 0.97% 5.00% Pass(4.0pp buffer)
MSCI M-Series Pass 4 of 4 ratios pass

Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 0.88% 33.33% Pass(32.5pp buffer)
Cash + interest-bearing securities 2.05% 33.33% Pass(31.3pp buffer)
Accounts receivable 2.76% 49.00% Pass(46.2pp buffer)
Non-permissible income 0.97% 5.00% Pass(4.0pp buffer)

Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.

How close is it to flipping?

Every current reading against its own line, closest first. A verdict is only as durable as that distance.

AAOIFI Standard 21 (% of market cap)non permissible income ratio 4.0pts
Usmani (% of total assets)non permissible income ratio 4.0pts
Dow Jones Islamic Market (% of 24-mo avg market cap)non permissible income ratio 4.0pts

The numbers the ratios are built from

Read from XVIPF's own filings. Every percentage on this page is one of these lines divided by another, so the inputs are shown rather than asserted.

LineFigureAs reportedRead from
RevenueTotal revenue for the period $88.2M 2025-12-31 yahoo:annualTotalRevenue
Interest-bearing debtShort and long-term borrowings $13.5M 2025-12-31 yahoo:annualTotalDebt
Cash and interest-bearing securitiesCash, equivalents and marketable securities $31.7M 2025-12-31 yahoo:annualCashCashEquivalentsAndShortTermInvestments
Total assetsBalance sheet total $257.8M 2025-12-31 yahoo:annualTotalAssets
Market capDenominator for AAOIFI $974.9M live quote price x shares
36-month average market capDenominator for S&P Shariah and MSCI M-Series $953.1M 756 trading days closes x shares
24-month average market capDenominator for Dow Jones Islamic Market $931.0M 504 trading days closes x shares
Non-permissible revenueInterest and excluded income $855.3K 2025-12-31 yahoo:annualInterestIncome

Two dates, not one: a balance-sheet line and an income-statement line cover different windows by design, so each figure carries its own.

Sources

Filing information. Balance sheet as of 2025-12-31. Income statement as of 2025-12-31. Screened 2026-09-08.

These figures came from Yahoo Finance fundamentals (Tier-4 provider, no filing available), not an SEC filing, so there is no EDGAR filing to link.

  • Total assets$257.8M
    yahoo:annualTotalAssets · balance sheet as of 2025-12-31
  • Interest-bearing debt$13.5M
    yahoo:annualTotalDebt · balance sheet as of 2025-12-31
  • Cash and interest-bearing securities$31.7M
    yahoo:annualCashCashEquivalentsAndShortTermInvestments · balance sheet as of 2025-12-31
  • Receivables$11.0M
    yahoo:annualAccountsReceivable · balance sheet as of 2025-12-31
  • Revenue$88.2M
    yahoo:annualTotalRevenue · income statement as of 2025-12-31
  • Interest income (non-permissible)$855.3K
    yahoo:annualInterestIncome · income statement as of 2025-12-31
  • Market cap$974.9M
    Market-data quote at screen time, 2026-09-08 · not a filing figure, so no link

What changed, and when

Verdict history for XVIPF. A verdict that never moved is recorded too, so a quiet history reads as measured rather than missing.

  • 2026-09-07 No change recorded No verdict change for XVIPF has been recorded since tracking began. The scan ledger records that the compliance detectors ran, not which symbols each pass covered.

Tracked since 2026-09-07.

What would change the status

The headline verdict is the majority of the decided ratio standards — 7 pass and 0 fail of 7 — with a business-activity screen and any hold applied on top. Balance sheet as of 2025-12-31; market cap as stored on 2026-09-08.

No standard's deciding ratio sits within 3 points of its line.

The ratios that move with the share price

AAOIFI's debt ratio (1.4% against a 30% line) would only fail if the market cap fell by 95%, to $45.1M.

AAOIFI's investments ratio (3.3% against a 30% line) would only fail if the market cap fell by 89%, to $105.7M.

Only AAOIFI divides by the market cap itself. The Dow Jones, S&P and MSCI M-Series standards divide by a 24- or 36-month average and the others by total assets, so a day's price move does not reach them. Figures are the screen's own; the live market cap differs from the stored one.

Shariah-compliant alternatives

Compliant companies in Medical Devices listed on the same market, largest first. Each is screened on its own; none carries a documented concern or a hold.

CompanyMarket capPrice, day
ABTAbbott Laboratories $201.9B —
SYKStryker Corp. $125.7B —
MDTMedtronic Plc $117.8B —
BSXBoston Scientific Corp. $71.0B —
EWEdwards Lifesciences Corp $52.2B —

A dash means no fresh quote is cached for that symbol; this list does not fetch one.

30.9527.5824.2020.8317.462025-11-192026-05-212026-11-17

Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset

Support & Resistance

This fund prices once a day, so its bars carry no intraday high or low — floor-trader pivots are not defined for it.

Price Forecast

The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally below. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.

7-day expected range
23.89 – 26.13
±4.49% from 25.01, made 2026-09-27 · resolves 2026-10-04
STRONG SELL
from 19 indicators
77.1% of our last 20463 forecasts — across every instrument we forecast, not just this one — landed inside their stated range, and 50.1% called the direction correctly.

Technical Summary

Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.

STRONG SELL
19 indicators
OscillatorsBUY
4 buy · 0 neutral · 3 sell
Moving averagesSTRONG SELL
0 buy · 0 neutral · 12 sell
Every indicator, and what it reads
IndicatorValueSignal
RSI (14)2.00BUY
Stochastic %K (14)0.00BUY
CCI (20)-154.97BUY
Williams %R (14)-100.00BUY
MACD (12,26,9)-0.04SELL
ROC (10)-12.36SELL
Momentum (10)-2.68SELL
EMA (10)20.19SELL
SMA (10)20.27SELL
EMA (20)20.87SELL
SMA (20)20.99SELL
EMA (30)21.54SELL
SMA (30)21.26SELL
EMA (50)22.72SELL
SMA (50)23.18SELL
EMA (100)24.08SELL
SMA (100)25.48SELL
EMA (200)23.52SELL
SMA (200)24.64SELL

About XVIPF

Healthcare · Medical Devices

Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden. It operates through Thoracic; Abdominal; Services; and other segments. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidneys with oxygenated solution for up to 24 hours; Liver Assist that provides clinicians a choice of perfusion protocols whether hypothermic, normothermic, sub-normothermic, or a combination; XVIVO System (XPS), a comprehensive ex vivo lung perfusion (EVLP) platform that offers an overview of the entire process; and STEEN Solution, a buffered extracellular solution intended for the assessment of isolated lungs after removal from the donor in preparation for eventual transplantation into a recipient. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XPS Disposable Lung Kit that contains all the necessary devices and tubing to run a normothermic EVLP procedure on the XPS; XVIVO Organ Chamber, a sterile single-use container intended to be used as a temporary receptacle for isolated donor lungs; and XVIVO Lung Cannula Set, a sterile single-use set that connects isolated donor lungs to an extracorporeal perfusion system for ex-vivo assessment. In addition, the company offers Kidney Assist that provides clinicians with a choice of perfusion protocols from hypothermic to normothermic perfusion; and Gisto, an integrated system for organ transportation. It operates in Sweden; The Netherlands; The United States; Italy; North and South America; Asia/Pacific and Oceania; and internationally. Xvivo Perfusion AB (publ) was incorporated in 1998 and is headquartered in Mölndal, Sweden.

xvivogroup.com ↗

Background via Yahoo Finance — informational, not part of the verdict.

SMC — Top Down

Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.

Not enough price history yet for a smart-money structure read on any timeframe.

Peer Movement

How the rest of the sector moved over the same window. Context for a price move, never a cause of one.

Peer movement computing — it will appear here on its own.

Before you act on this

The questions worth asking about any verdict on this page, answered plainly.

Is this a fatwa?

No. HTR applies published screening standards to a company's own filings and shows the result under each one. It is research, not a religious ruling. For a ruling that applies to you, ask a qualified scholar.

Why can the standards disagree?

Because they measure different things. Some divide interest-bearing debt by market cap, others by total assets, and the thresholds differ too. The same filing can clear one line and cross another. HTR shows every verdict rather than averaging them into one label.

How often is this re-screened?

Ratios are recomputed when a new filing lands, and the whole watchlist is re-screened on a rolling basis. The date on the verdict above is the last time this symbol was actually recomputed, not the last time the page was built.

Do I need to purify dividends?

If a company earns some non-permissible income, many scholars hold that the same share of any dividend should be given away. The non-permissible income figure above is the number that calculation starts from — the purification calculator finishes it, showing the filing figures behind the ratio and both the proportional and the AAOIFI per-share convention.

Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.

Compare with

Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.

Peer screening computing — it will appear here on its own.

Insider Activity (90d)

Insider transactions reported in the last ninety days. Insiders sell for reasons that have nothing to do with a view, so a sale on its own is not a signal.

NO DATA   0 buys · 0 sells

COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE

The weekly CFTC Commitments of Traders report for the broad market it tracks, not for this symbol. Positioning context for the tape — it says nothing about this company.

NEUTRAL   report date 2026-11-10 · Asset managers net 914130 (-14454)

AI Summary

Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.